Bristol-Myers Squibb Stock Is Too Cheap to Ignore

Bristol-Myers Squibb's (NYSE: BMY) decision to acquire Celgene in a cash and stock transaction valued at $74 billion wasn't particularly well-received. For instance, one of the company's largest institutional shareholders -- Wellington Management -- came out in opposition of the deal on the grounds that it put unnecessary risk on Bristol-Myers' shareholders. Also, the U.S. Federal Trade Commission (FTC) expressed antitrust concerns after the acquisition was announced. Bristol-Myers sold Celgene's psoriasis drug Otezla to Amgen (NASDAQ: AMGN) for $13.4 billion in cash to appease government regulators.

Despite all of these challenges, Bristol-Myers officially closed its acquisition of Celgene on Nov. 20, 2019. And in its first earnings release since then, the pharma company showed just why it spent a fortune on this blockbuster deal. 

Image source: Getty Images.

Continue reading

Source Fool.com